Understanding the components of pharmaceutical expenditure—overview of pharmaceutical policies influencing expenditure across European countries
Author(s): 1 Sabine Vogler, PhD, 2 Nina Zimmermann, MA, Claudia Habl
Aim: To explain the components of pharmaceutical expenditure and illustrate the strengths and limitations of this indicator. In particular, we explore policies applied in European countries that affect the price… Read More »
Safety and toxicity of biosimilars—EU versus US regulation
Author(s): 1 Tobias Blank, PhD, Angela Vogt-Eisele, PhD, Professor Marietta Kaszkin-Bettag, PhD, Tilo Netzer, PhD, Wolfram Hildebrandt, MSc, MA
Author byline as per print journal: Tobias Blank, PhD, Tilo Netzer, PhD, Wolfram Hildebrandt, MSc, MA, Angela Vogt-Eisele, PhD, Professor Marietta Kaszkin-Bettag, PhD Background: As patents for biological drugs begin… Read More »
Steps to ensure adequate supply of biological medicines: considerations for the healthcare provider
Author(s): Andrew Mica, MBA, et al.
Author byline as per print journal: Andrew Mica, MBA, Martha Mutomba, PhD, Larry Green, PharmD Introduction: When drug shortages occur, healthcare providers (HCPs) often must ration drugs, cancel or delay… Read More »
Pharmacokinetics of antimicrobials in obese children
Author(s): 1 Mario R Sampson, PharmD, et al.
Author byline as per print journal: Mario R Sampson, PharmD; Michael Cohen-Wolkowiez, MD, PhD; Professor Daniel Kelly Benjamin Jr, MD, MPH, PhD; Edmund V Capparelli, PharmD; Kevin M Watt, MD… Read More »
Biosimilars in the European market
Author(s): Antonio Olry de Labry, PhD, Emmanuel Giménez, BSc, Leandro Lindner, BSc, Leticia García, BSc, Professor Jaime Espín, PhD, Professor Joan Rovira, PhD
Author byline as per print journal: Professor Joan Rovira, PhD; Leandro Lindner, BSc; Emmanuel Giménez, BSc; Professor Jaime Espín, PhD; Antonio Olry de Labry, PhD; Leticia García, BSc Introduction and… Read More »
Current status of biopharmaceuticals in Iran’s pharmaceutical market
Author(s): Professor Abdol Majid Cheraghali, PharmaD, PhD
Abstract: The clinical importance of biopharmaceuticals for the management of life threatening diseases is increasing but costs have become a major obstacle to the administration of these medicines, especially in… Read More »
Assessing biosimilarity and interchangeability of biosimilar products under the Biologics Price Competition and Innovation Act
Author byline as per print journal: Professor Shein-Chung Chow, PhD, Christine Ju, MSc Abstract: Biological (large molecule) drug products are made via living systems and are complex and variable in nature.… Read More »
Reference pricing systems in Europe: characteristics and consequences
Author(s): Pieter Dylst, PharmD, Professor Arnold G Vulto, PharmD, PhD, FCP, Steven Simoens, MSc, PhD
Author byline as per print journal: Pieter Dylst, PharmD; Professor Steven Simoens, MSc, PhD; Professor Arnold G Vulto, PharmD, PhD Introduction: A reference pricing system is a system that establishes a common reimbursement level… Read More »
Payers endorse generics to enhance prescribing efficiency: impact and future implications, a case history approach
Author(s): Brian Godman, BSc, PhD, et al.
Author byline as per print journal: Brian Godman1,2,3, BSc, PhD; Mohammed Abuelkhair4, PharmD; Agnes Vitry5, PharmD, PhD; Shajahan Abdu4, MD; Marion Bennie6,7, MSc; Iain Bishop7, BSc; Sahar Fahmy4, PhD; Kristina Garuoliene8,… Read More »
What lessons can be learned from the launch of generic clopidogrel?
Author(s): Christoph Baumgärtel, MD, MSc, et al.
Author byline as per print journal: Christoph Baumgärtel1, MD; Brian Godman2,3,4, BSc, PhD; Rickard E Malmstrom5, MD, PhD; Morten Andersen6, MD, PhD; Mohammed Abuelkhair7, PharmD; Shajahan Abdu7, MD; Marion Bennie8,9, MSc;… Read More »